Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire

被引:139
作者
Bodger, Keith [1 ,2 ]
Ormerod, Clare [1 ,2 ]
Shackcloth, Daniela [2 ]
Harrison, Melanie [2 ]
机构
[1] Univ Liverpool, Dept Gastroenterol, Inst Translat Med, Liverpool L69 3BX, Merseyside, England
[2] Aintree Univ Hosp NHS Fdn Trust, Digest Dis Ctr, Liverpool L9 7AL, Merseyside, England
关键词
QUALITY-OF-LIFE; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; CLINICAL-TRIALS; HEALTH-STATUS; INSTRUMENT; INDEX; COST; CARE; UK;
D O I
10.1136/gutjnl-2013-305600
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction The use of patient reported outcome measures to support routine inflammatory bowel disease (IBD) care is not widespread and suggests that existing questionnaires lack relevance to day-to-day decisions or are too cumbersome to administer. We developed a simple, generic tool for capturing disease control from the patient's perspective to address these barriers. Methods Development based on literature review, patient focus groups/interviews and a steering group, defining a limited set of generic questions. The 'IBD-Control' questionnaire comprises 13 items plus a visual analogue scale (VAS) (0-100). Prospective validation involved baseline completion of IBD-Control, quality of life (QoL) questionnaire (UK-IBD-Q), EuroQol (EQ-5D), Hospital Anxiety and Depression Score; and clinician assessment (blinded to questionnaire; recording Harvey-Bradshaw Index or Simple Clinical Colitis Activity Index; Global Clinician Rating; treatment outcome). Results 299 patients returned baseline surveys (Crohn's disease, n=160; ulcerative colitis, n=139) and 138 attended for repeat visits. Completion time (mean; SD): 1 min 15 s; 25 s; Internal consistency: Cronbach's alpha for all 13 items (0.85); for subgroup of eight questions ('IBD-Control-8'; 0.86). Strong correlation between IBD-Control-8 and IBD-Control-VAS (r=0.81). Test-retest reliability (2 week repeat): intra-class correlation=0.97 for IBD-Control-8 and 0.96 for IBD-Control-VAS. Construct validity: Moderate-to-strong correlations between IBD-Control-8 and IBD-Control-VAS versus activity indices, UK-IBD-Q and EQ-5D (utility) with r values 0.52-0.86. Discriminant validity (mean instrument scores for remission, mild, moderate or severe): p<0.001 (analysis of variance (ANOVA)). Sensitivity to change: Effect sizes: 0.76-1.44. Conclusions The IBD-Control is a rapid, reliable, valid and sensitive instrument for measuring overall disease control from the patient's perspective. Unlike existing patient reported outcome measures, its simplicity, ease-of-use and generic applicability make it a candidate for supporting routine care.
引用
收藏
页码:1092 / 1102
页数:11
相关论文
共 32 条
  • [1] Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures
    Achleitner, Ulrike
    Coenen, Michaela
    Colombel, Jean-Frederic
    Peyrin-Biroulet, Laurent
    Sahakyan, Narine
    Cieza, Alarcos
    [J]. JOURNAL OF CROHNS & COLITIS, 2012, 6 (05) : 507 - 517
  • [2] [Anonymous], HLTH TECHNOL ASSESS
  • [3] [Anonymous], UK INFL BOW DIS AUD
  • [4] Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study
    Bassi, A
    Dodd, S
    Williamson, P
    Bodger, K
    [J]. GUT, 2004, 53 (10) : 1471 - 1478
  • [5] BEST WR, 1976, GASTROENTEROLOGY, V70, P439
  • [6] Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire
    Casellas, F
    Alcalá, MJ
    Prieto, L
    Miró, JRA
    Malagelada, JR
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (03) : 457 - 461
  • [7] The UK IBDQ - A British version of the inflammatory bowel disease questionnaire: development and validation
    Cheung, WY
    Garratt, AM
    Russell, IT
    Williams, JG
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2000, 53 (03) : 297 - 306
  • [8] The quality of life in patients with Crohn's disease
    Cohen, RD
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (09) : 1603 - 1609
  • [9] Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation
    Cooney, Rachel M.
    Warren, Bryan F.
    Altman, Douglas G.
    Abreu, Maria T.
    Travis, Simon P. L.
    [J]. TRIALS, 2007, 8 (1)
  • [10] Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297